Making the Move to AAV producer cell lines: comparability, bridging studies and regulatory considerations
•BioInsights•Season 5•Episode 5
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
28:37
Lauren Coyle(Editor, BioInsights)speaks withLonza'sLaura Sands(Head of Regulatory Affairs), Ramesh Koukuntla(Director of R&D), Wenling Dong (Head of Upstream Process Development), and Vijetha Bhat (Subject Expert of Platform Technologies) about:
Key regulatory considerations when transitioning to AAV producer cell lines
Comparability and bridging strategies to support a successful transition
Approaches to managing manufacturing and regulatory risk
Considerations for enabling scalable AAV production
1. Transient transfection got the first wave of AAV gene therapies to patients; its flexible, it is well understood, and for early clinical work, it does the job, but it is not where the field is settling. What are the limitations of transient transfectio
2. There is sometimes a temptation to see this as swapping one upstream step for another, but is it more than that? When a company makes this move, what genuinely changes from a manufacturing standpoint?
3. Wenling, you take these process from development through to GMP. Beyond titer, which quality and performance attributes should sponsors be watching most closely as they compare the two?
4. Where do you think teams most often get caught up during this process development?
5. Timing is just about whether you make the switch, but also when you make the switch. From a company engineering or completing Phase 1, what are the signals that tell you that it is time so evaluate a producer cell line strategy?
6. With these discussions being early with the CDMO partners, what do you think the repercussions would be if they happened slightly later than anticipated?
7. Why is a switch like this treated as a manufacturing process change rather than a simple material change, and when a regulator looks at it, what is the central question that they are trying to ask?
8. If transitioning to a producer cell line, does that automatically mean a clinical bridging study, and how does that answer change depending on whether the move is made before IND, during Phase 1, or if it was later in development?
9. Is there a point of no return where that burden jumps significantly?
10. From where you each sit, what would you say determines whether analytical comparability alone will carry that versus when you genuinely need non-clinical or clinical bridging data?
11. Looking ahead 5 years, do you expect producer cell lines to become the preffered manufacturing approach for a significant proportion of AAV programs, and if so, what is going to drive that shift?
